Navigation Links
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
Date:1/30/2008

danani of the Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation."

Cytopia's Research Director Dr Chris Burns stated: "This data is important validation that our selective JAK2 inhibitors stop the proliferation of mutant cells from patients with these diseases at clinically achievable doses."

Cytopia is developing JAK2 inhibitors for the treatment of MPDs and other solid and blood cancers. In addition, other inhibitors of JAK2 are under development for cardiovascular and ophthalmic diseases.

About Cytopia

Cytopia Ltd is an Australian headquartered biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au

Relevant Links:

http://www.mpdfoundation.org

http://www.mpd-oz.org


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
9. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today ... HYLENEX manufacturing and has identified a corrective action plan ... Halozyme and Baxter are finalizing the materials for a ... seek concurrence with the reintroduction strategy. During several meetings ...
... LONDON, Aug. 31 Following a recent analysis ... Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with ... Leadership Award".  Statscan, Lodox,s digital x-ray product, stunned ... diagnostic, whole-body x-ray pictures in just 13 seconds. ...
Cached Medicine Technology:Halozyme Provides HYLENEX® Product Reintroduction Update 2Halozyme Provides HYLENEX® Product Reintroduction Update 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 2Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 3Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products 4
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Saving Benefit Faces Eventual Elimination Without Relief , ... of President Obama,s pledge not to raise taxes on the ... outside of the normal legislative process -- adopting provisions approved ... the use of flexible spending accounts (FSAs) in order to ...
... from a new virtual reality training programme created at ... have been working with researchers in the School of ... scenarios that test expert players, perceptual skills. Lead ... Senior Lecturer in Visual Perception who has previously collaborated ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on ... at 6:00 PM on Channel 21. , ... Health Clinics with Erin Buckley, FNP-C, Certified Family Nurse ...
... Oct. 14 Peter Sheldon, Vice President of Operations ... commercial cleaning businesses, will be a featured speaker at ... to be held on October 14-15 at The Fairmont ... is "Be the Best in Your Business with Best ...
... 15, 2009 marks the 35th anniversary of the founding of ... McDonald Houses in 52 countries and regions throughout the world, ... the Philadelphia House,s two locations (on Chestnut Street, and at ... McDonald House of Southern New Jersey, the world,s 51st House, ...
... ... a few years ago, today it seems "Natural" is the new buzz word in retail, ... Buster was recently featured on an episode of The Dr. Oz Show in a segment ... ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:Increased success a 'virtual' certainty for rugby players 2Health News:Retail Health Clinics - The Real Story 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 2Health News:Philadelphia-Born Ronald McDonald House(R) Program Celebrates 35 Years 3Health News:Sinus Buster Paves the Way for Natural OTC Products and Mainstream Success 2
Lambotte periosteal elevators....
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
Medicine Products: